Vela Rx review

Vela Rx provides a named platform operator and detailed subscription terms, but its advertised starting price is not a confirmed long-term quote. Compare the prescribed quantity and renewal bill, and get the applicable cancellation rule in writing before authorizing recurring charges.

Vela Rx is a telehealth platform whose terms and privacy policy identify TBF Supplements LLC as the website operator. Both policies publish a mailing address in Sheridan, Wyoming. That identifies the business taking responsibility for the platform; it does not identify the medical practice that will treat an individual patient. The terms say independent providers make clinical decisions and partner pharmacies prepare and dispense prescriptions. Vela Rx itself does not practice medicine or dispense medication.

The public catalog includes compounded semaglutide and tirzepatide injections, a lower-dose GLP-1 program and NAD⁺ therapy. Those are separate offers, not evidence that a GLP-1 purchase includes every service. The public pages reviewed here do not name the assigned medical group or dispensing pharmacy. Obtain both names for the selected prescription, along with the pharmacy label, rather than relying on the platform brand alone.

The advertised process starts with an online assessment, followed by review by a licensed provider and a prescription only if appropriate. Treatment pages describe ongoing check-ins, provider-directed adjustments and secure messaging. They do not establish the exact appointment format or frequency for a particular plan. Ask whether your assessment requires video, when follow-up occurs and how to reach the treating clinician between reviews. A general support response and a clinical consultation serve different purposes.

The homepage advertises nationwide telehealth. The terms are narrower: service is available in states where the operator works, users must be at least 18 or the higher local age of majority, and their physical location during consultation must match the state of their shipping address. A state-by-state availability list was not established from the reviewed public pages. Confirm access to your specific treatment, rather than assuming a nationwide headline covers every address and product.

Free two-to-three-day shipping is advertised on the homepage. The terms describe delivery dates as estimates, so that shipping statement is not a promise that assessment, prescribing and delivery together take two or three days.

The homepage displays semaglutide and tirzepatide plans from $149 per month. It also shows crossed-out figures of $199 and $269 respectively. Those reference figures do not establish the renewal price, duration of a promotion, dose or amount supplied. Do not turn either advertisement into an annual cost estimate without a written quote for the actual prescription. The page says plans are confirmed after provider review.

Treatment FAQs describe flat-rate pricing without consultation charges or dose-change surcharges. The terms say a subscription bundles the pharmacy, medical-group and platform portions of the price. They also permit applicable taxes and any shipping or handling charges displayed at purchase. Confirm which costs apply to the selected plan, including supplies, labs and any separately purchased treatment. “No insurance required” establishes an advertised purchase route without coverage, not a promise that an insurer will reimburse it.

For a recurring monthly order, the terms authorize an immediate charge followed by charges every 30 days. They describe an electronic notice five to seven days before a scheduled transaction. That is automatic billing, not a refill that happens only after a new manual purchase. The homepage’s $0-if-not-approved statement should be read alongside the refund conditions; it does not establish that no payment authorization occurs before clinical review.

The homepage lists semaglutide and tirzepatide injection plans, and their treatment pages include compounded medication in the advertised programs. Vela Rx’s disclaimer states that compounded medicines are not FDA-approved and are not the same as the branded products featured in its trial discussion. A trial graphic, customer story or starting price does not verify the contents or performance of an individual prescription.

The selected concentration, vial quantity, additives, supplied duration and dispensing pharmacy need confirmation. The public product descriptions refer generally to partner U.S. compounding pharmacies without naming the one assigned to an order. The terms also say prescriptions are filled through platform pharmacies rather than a pharmacy chosen independently by the customer.

Lower-dose GLP-1 and NAD⁺ products appear in the catalog, but their exact prescribed formulation, supply and price are not established by the GLP-1 price cards. Their marketing does not show that they are appropriate for a particular reader or equivalent to an approved branded treatment. Those decisions belong with the treating clinician.